Lizzy Smyth
@lizzysmyth.bsky.social
Oncologist. Cancer Research 👩⚕️. Clinical Trials 🧬💊. Oxford Irish. #Oncsky
❓ Should we switch chemotherapy for patients with gastroesophageal cancer after 3 months?
ARMANI trial published in Lancet Oncol today
✔️ Patients who switched to 2L pac/ram after 3m of OxFU had ⬆️ PFS and OS than patients who continued 1L chemo
❌....but also ⬆️ hospital visits & toxicity.
November 19, 2024 at 4:25 PM
❓ Should we switch chemotherapy for patients with gastroesophageal cancer after 3 months?
ARMANI trial published in Lancet Oncol today
✔️ Patients who switched to 2L pac/ram after 3m of OxFU had ⬆️ PFS and OS than patients who continued 1L chemo
❌....but also ⬆️ hospital visits & toxicity.
👏 Great to see this published!
VESTIGE is a negative randomised trial with an important lesson..
➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo.
👀 Looking forward to the translational work
annalsofoncology.org/article/S0923-…
VESTIGE is a negative randomised trial with an important lesson..
➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo.
👀 Looking forward to the translational work
annalsofoncology.org/article/S0923-…
November 14, 2024 at 9:55 PM
👏 Great to see this published!
VESTIGE is a negative randomised trial with an important lesson..
➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo.
👀 Looking forward to the translational work
annalsofoncology.org/article/S0923-…
VESTIGE is a negative randomised trial with an important lesson..
➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo.
👀 Looking forward to the translational work
annalsofoncology.org/article/S0923-…